NDC 68788-7944-09 - Levothyroxine sodium
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 68788-7944
- Requested NDC
- 68788-7944-09
- Package NDCs from labels
- 68788-7944-3, 68788-7944-9, 68788-7944-1, 68788-7944-09
- Manufacturer
- Preferred Pharmaceuticals Inc.
- Effective date
- 2026-05-21
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Levothyroxine sodium - Preferred Pharmaceuticals Inc. | Preferred Pharmaceuticals Inc. | 2026-05-21 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68788-7944-1 | Levothyroxine sodium | 100 in 1 BOTTLE | TABLET | 100 | 6 | |
| 68788-7944-3 | Levothyroxine sodium | 30 in 1 BOTTLE | TABLET | 30 | 6 | |
| 68788-7944-9 | Levothyroxine sodium | 90 in 1 BOTTLE | TABLET | 90 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68788-7944 | LEVOTHYROXINE SODIUM TABLET [PREFERRED PHARMACEUTICALS INC.] | 4 | Current NDC, Legacy NDC, 3 package rows | 20240615_6d65b528-f52b-4b5d-8b76-46fbd4576f99.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68788-7944-1 | EA - Each | 68788-7944 | ef7bcfba-95f5-48d0-a9d1-3a2b2fb5210f | 1 | 2022-11-07 |
| 68788-7944-3 | EA - Each | 68788-7944 | 5cc87cee-623c-4d3b-8419-6b2a8c05247e | 1 | 2022-11-07 |
| 68788-7944-9 | EA - Each | 68788-7944 | 3e3dcb50-8a70-4b88-9d10-3f02548f9d1b | 1 | 2022-11-07 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 8849620a-5e8d-4031-884f-9a2817b050f2 | 2026-11-09 | Boxed warning, Warnings, Adverse reactions | 9J765S329G |
| LEVOXYL | LEVOTHYROXINE SODIUM | Pfizer Laboratories Div Pfizer Inc | 758588c3-c63e-491b-0aa2-4f50d80cb174 | 2026-11-06 | Boxed warning, Warnings, Adverse reactions | 966248 892251 966222 966270 892246 966221 966224 966249 966220 966225 966253 9J765S329G |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | fc803107-aaa2-4753-ab97-7b4ed5cf4be5 | 2026-11-05 | Boxed warning, Warnings, Adverse reactions | 966222 9J765S329G |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 3b282e57-1009-4d2c-8ca2-9cca9f791937 | 2026-11-05 | Boxed warning, Warnings, Adverse reactions | 966220 9J765S329G |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | d35b5250-c26d-4d67-8a33-2f993b13e3e9 | 2026-11-05 | Boxed warning, Warnings, Adverse reactions | 892246 9J765S329G |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 48c29432-a36c-4787-a05f-8d25a0abcc37 | 2026-11-04 | Boxed warning, Warnings, Adverse reactions | 966222 9J765S329G |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | c1b0fbad-5816-4152-ab59-05079e8c2148 | 2026-11-02 | Boxed warning, Warnings, Adverse reactions | 966221 9J765S329G |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 3e77de84-6f59-40ac-a1a4-7bfe30387823 | 2026-10-27 | Boxed warning, Warnings, Adverse reactions | 966225 9J765S329G |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | REMEDYREPACK INC. | 0fa2e2f5-401b-45c1-b6a5-d02f6faf509d | 2026-10-27 | Boxed warning, Warnings, Adverse reactions | ANDA212399 966248 9J765S329G |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | c22af2e0-fb36-4645-a911-3d293af5bd88 | 2026-10-26 | Boxed warning, Warnings, Adverse reactions | 966221 9J765S329G |
| Mag 440 | MEGNESIUM OXIDE | Allegis Pharmaceuticals, LLC | 2cb19dc0-115b-38b8-e063-6294a90a4aea | 2026-10-26 | Warnings | 3A3U0GI71G |
| magnesium oxide | MAGNESIUM OXIDE | Marlex Pharmaceuticals Inc. | dc57893c-068a-37d8-e053-2a95a90aa054 | 2026-10-26 | Warnings | 3A3U0GI71G |
| Magnesium Oxide | MAGNESIUM OXIDE | Marlex Pharmaceuticals Inc | 0bb322a5-fb92-14de-e063-6294a90a4c1b | 2026-10-26 | Warnings | 3A3U0GI71G |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | d79526e0-d327-4545-a50c-99678766d817 | 2026-10-26 | Boxed warning, Warnings, Adverse reactions | 966220 9J765S329G |
| PNV-Omega | ASCORBIC ACID, CHOLECALCIFEROL, .ALPHA.-TOCOPHEROL, PYRIDOXINE HYDROCHLORIDE, FOLIC ACID, CYANOCOBALAMIN, CALCIUM CORBONATE, FERROUS FUMARATE, POTASSIUM IODIDE, MAGNESIUM, DOCONEXENT, ICOSAPENT | Acella Pharmaceuticals, LLC | 735c5531-137f-4cee-8c68-ae121045a8ff | 2026-10-23 | Boxed warning, Adverse reactions | 3A3U0GI71G |
| Folivex | MULTIVITAMIN | Oncora Pharma, LLC | 98b4a821-c139-4e9b-99c7-6451af6c27ce | 2026-10-22 | Warnings, Adverse reactions | 3A3U0GI71G |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | 5da80d6d-4895-ad6c-e063-6394a90ae6f5 | 2026-10-12 | Boxed warning, Warnings, Adverse reactions | 966224 9J765S329G |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals,Inc. | 5da82b4e-bf84-c482-e063-6394a90addf9 | 2026-10-12 | Boxed warning, Warnings, Adverse reactions | 892246 9J765S329G |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | 8bc641d8-0185-49b2-9c1f-d886bf5ce098 | 2026-10-07 | Boxed warning, Warnings, Adverse reactions | 966221 9J765S329G |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Proficient Rx LP | 1a2124e6-aea2-40dd-bb8d-52c58405a67e | 2026-10-01 | Boxed warning, Warnings, Adverse reactions | 966222 9J765S329G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.